PMS-PIOGLITAZONE TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE)

Saadav alates:

PHARMASCIENCE INC

ATC kood:

A10BG03

INN (Rahvusvaheline Nimetus):

PIOGLITAZONE

Annus:

30MG

Ravimvorm:

TABLET

Koostis:

PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 30MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

THIAZOLIDINEDIONES

Toote kokkuvõte:

Active ingredient group (AIG) number: 0141541002; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2007-12-05

Toote omadused

PRODUCT MONOGRAPH
PR
PMS-PIOGLITAZONE
Pioglitazone Hydrochloride Tablets
15 mg, 30 mg, 45 mg
USP
Anti-Diabetic Agent
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
Date of Revision:
May 14, 2018
www.pharmascience.com
Submission Control No: 215147
_pms-PIOGLITAZONE Product Monograph _
_Page 2 of 46_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
9
DRUG INTERACTIONS
.........................................................................................................
13
DOSAGE AND ADMINISTRATION
.....................................................................................
15
OVERDOSAGE
.......................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 17
STORAGE AND STABILITY
.................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
24
PHARMACEUTICAL INFORMATION
.................................................................................
24
CLINICAL TRIALS
..........................................................